Romanian Journal of Infectious Diseases Logo
  • Home
  • Aims & Scope
  • Standards
    • Editorial policies
    • Instructions for authors
    • Peer review process
    • Guidelines for Reviewers
    • Ethics and Malpractice policies
    • Official Journal’s protocols & statements
    • Open Access
    • Fees
  • Editorial Council
  • Peer Review Council
  • EMC | CME
  • How to
  • SUBSCRIBE
  • Menu

Arhiva autor

  • About
  • Latest Posts

Petre Iacob Calistru

Latest posts by Petre Iacob Calistru (see all)

  • TRATAMENTUL PRELUNGIT CU AZITROMICINA LA BOLNAVII CU BRONHOPNEUMOPATIE OBSTRUCTIVA CRONICA SI INFECTII CRONICE RESPIRATORII - 26/08/2015
  • SINDROMUL DE INTESTIN IRITABIL SI PROBIOTICELE - 26/08/2015
  • NIVELUL BNP (POLIPEPTIDUL NATRIURETIC TIP B) IN EXACERBARILE INFECTIOASE ALE BRONHOPNEUMOPATIEI CRONICE OBSTRUCTIVE - 25/08/2015

Articole semnate de acelasi autor in Revista Romana de Boli Infectioase:

TRATAMENTUL PRELUNGIT CU AZITROMICINA LA BOLNAVII CU BRONHOPNEUMOPATIE OBSTRUCTIVA CRONICA SI INFECTII CRONICE RESPIRATORII

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XV, No. 1, Year 2012
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

TRATAMENTUL PRELUNGIT CU AZITROMICINA LA BOLNAVII CU BRONHOPNEUMOPATIE OBSTRUCTIVA CRONICA SI INFECTII CRONICE RESPIRATORII

Maria Zlatev Ionescu, Olimpia Nicolaescu, Lia Popescu, Mihaela Cîrstea, Emilia Ciomu, Maria Nica, Iuliana Apostol, Petre Iacob Calistru and Emanoil Ceauşu

REZUMAT

Lucrarea prezintă etiologia infecţiilor recurente şi efectele azitromicinei administrată prelungit la bolnavi cu bronhopneumopatie obstructivă cronică (BPOC). Rezultate. La 25 de pacienţi cu BPOC, s-au studiat etiologia bacteriană a infecţiilor recurente şi efectele administrării de azitromicină 500 mg la 2 zile, timp de 6 luni, cu reevaluare după 3 luni de pauză. S-a înregistrat creşterea calităţii vieţii prin chestionarul St. George de calitate al vieţii la bolnavii respiratori (scorul simptome 71,62±34,45 se reduce la 60,15±27,58 scorul total scade de la 65,95±27,69 la 57,53±18,18 unităţi, p<0,01). La 60% dintre pacienţi s-a izolat floră patogenă în spută sau aspiratul bronşic astfel: Pseudomonas aeruginosa la 32%, H. influenzae 8%. Acinetobacter, E. Coli, sau Klebsiella pneumoniae câte 4% şi Streptococcus pneumoniae 8%. Numărul de exacerbări care au necesitat internare s-a redus de la 3±2 timp de 12 luni la 1 timp de 9 luni. Numărul de zile de spitalizare pe perioada studiată s-a redus semnificativ de la 36±20 zile per bolnav şi, pe an, la 3±12 timp de 9 luni. Concluzii. Etiologia infecţiilor respiratorii recurente este dominată de germenii gram negativi, iar administrarea prelungită de azitromicină duce la creşterea calităţii vieţii prin ameliorare simptomatică şi reducerea numărului de exacerbări care necesită spitalizare.

Cuvinte cheie: bronhopneumopatie cronică obstructivă, infecţii respiratorii cronice, azitromicină

Full text | PDF

SINDROMUL DE INTESTIN IRITABIL SI PROBIOTICELE

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XV, No. 2, Year 2012
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

SINDROMUL DE INTESTIN IRITABIL SI PROBIOTICELE

Horaţiu Teodorescu and Petre Iacob Calistru

REZUMAT

Sindromul de intestin iritabil este una dintre cele mai frecvente afecţiuni digestive cu care se confruntă gastroenterologul şi medicul de familie – în populaţia mondială incidenţa este de 1-2% (2,3,14,19,22). Este caracterizat prin durere abdominală sau disconfort, accentuate de defecaţie sau meteorism şi asociate cu modificări în frecvenţa şi consistenţa scaunelor. În momentul de faţă nu există teste diagnostice specifice pentru SII. Diagnosticul se pune prin excluderea altor boli cu care are o parte de simptomatologie comună sau folosind criterii bazate pe simptome, criterii validate în studii „cross sectional“ sau longitudinale (criteriile Roma III). Modificările observate în compoziţia florei microbiene fecale, incidenţa înaltă de apariţie a sindromului de intestin iritabil (SII) după episoadele de infecţie gastrointestinală, alterările imune ale sistemului digestiv la pacienţii cu SII şi observaţia că probioticele pot conduce la ameliorarea simptomelor SII au stabilit o nouă direcţie în managementul acestei afecţiuni.

Cuvinte cheie: sindrom de intestin iritabil, tratament, probiotic

Full text | PDF

NIVELUL BNP (POLIPEPTIDUL NATRIURETIC TIP B) IN EXACERBARILE INFECTIOASE ALE BRONHOPNEUMOPATIEI CRONICE OBSTRUCTIVE

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XV, No. 2, Year 2012
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

NIVELUL BNP (POLIPEPTIDUL NATRIURETIC TIP B) IN EXACERBARILE INFECTIOASE ALE BRONHOPNEUMOPATIEI CRONICE OBSTRUCTIVE

Simona Ştefania Bucşa, Cristina Voinea and Petre Iacob Calistru

REZUMAT

Exacerbările bronhopneumopatiei cronice obstructive (BPOC) reprezintă o perioadă din evoluţia naturală a bolii, influenţând, prin frecvenţa şi severitatea lor, prognosticul vital al pacientului cu BPOC. Este şi motivul pentru care ultimele cercetări s-au concentrat asupra unor indicatori de prognostic la pacienţii cu exacerbări BPOC. Polipeptidul natriuretic tip B (Brain natriuretic polypeptide BNP) se consideră că poate reprezenta un marker noninvaziv util ca parametru predictor şi prognostic al exacerbării BPOC, noi informaţii şi rezultate în această direcţie fiind în beneficiul pacienţilor.

Cuvinte cheie: exacerbările bronhopneumopatiei cronice obstructive, infecţii bronhopulmonare, BNP (Polipeptidul natriuretic tip B)

Full text | PDF

BENEFICII CLINICE ALE PROBIOTICELOR LA PACIENTII CU SINDROM DE INTESTIN IRITABIL

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XV, No. 4, Year 2012
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

BENEFICII CLINICE ALE PROBIOTICELOR LA PACIENTII CU SINDROM DE INTESTIN IRITABIL

Horaţiu Iustinian Teodorescu, Alexandru Ciric, Alma Gabriela Koşa and Petre Iacob Calistru

REZUMAT

Sindromul intestinului iritabil (SII) este un diagnostic de tip tulburare funcţională din apanajul medicinei moderne, care are un impact important asupra calităţii vieţii individului. Contribuţia disbiozei microflorei intestinale la declanşarea unor afecţiuni este deja acceptată, în literatură vorbindu-se despre acest ecosistem ca „organ funcţional“, care poate fi influenţat prin medicaţie. Probioticele sunt microorganisme vii, administrate sub diverse forme farmaceutice/alimente nutraceutice (iaurt), pentru tratamentul SII, pornind de la conceptul că vor influenţa benefic acest ecosistem. Studiile clinice în domeniu trebuie să se bazeze pe metode subiective de apreciere a efectului terapeutic, dar şi pe metode obiective, de punere în evidenţă a probioticului la locul de acţiune şi, nu în ultimul rând, corelarea celor 2 tipuri de rezultate.

Cuvinte cheie: calitatea vieţii, microfloră intestinală, probiotic

Full text | PDF

INFECTIA CU VHC SI ATEROSCLEROZA SUBCLINICA

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XVI, No. 3, Year 2013
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

INFECTIA CU VHC SI ATEROSCLEROZA SUBCLINICA

Angelica Nour-Dincă and Petre Iacob Calistru

REZUMAT

Obiectiv. Implicarea virsului hepatitic C (VHC) în ateroscleroză este un subiect controversat. Ateroscleroza subclinică este o etapă premergătoare apariţiei complicaţiilor cardiovasculare severe, iar decelarea ei prin ultrasonografie carotidiană are importanţă deosebită în stratificarea riscului cardiovascular şi a atitudinii terapeutice.

Material şi metodă. 71 pacienţi cu hepatită C şi 51 pacienţi control, comparabili ca vârstă, sex şi factori de risc cardiovasculari au fost evaluaţi clinic, prin determinări de laborator şi ecografic, măsurarea grosimii intimă-medie carotidiană şi ecografie abdominală.

Rezultate. Pacienţii cu hepatită C au un profil dismetabolic particular, fiind mai supraponderali, cu valori mai mari ale glicemiei, chiar în absenţa diabetului zaharat şi cu valori mai mici ale colesterolemiei şi trigliceridemiei, comparativ cu grupul de control comparat, cu semnificaţie statistică (p < 0,05). Indicele grosimii intimă-medie a fost mai mare la grupul cu hepatită C faţă de grupul de control (0,88 ± 0,05 vs 0,76 ± 0,08 mm, p < 0,01), iar numărul plăcilor de aterom descrise a fost mai mare la pacienţii cu hepatită C (42% vs 14%, p = 0,006). De asemenea, prevalenţa steatozei hepatice a fost mai mare în grupul cu hepatită C (41% vs 12%, p = 0,007). Pacienţii cu hepatita C non-viremici au profil metabolic asemănător cu grupul de control, dar au indicele intimă-medie mai mare (0,86 ± 0,05 vs 0,76 ± 0,08 mm, p < 0,001).

Concluzii. Identificarea aterosclerozei subclinice în infecţia cu VHC poate ajuta la definirea unui nou factor de risc cardiovascular – virusul hepatitic C, cu implicaţii importante in morbiditate şi mortalitate.

Cuvinte cheie: virus hepatitic C, ateroscleroză, inflamaţie cronică, boală sistemică, grosime indice-medie

Full text | PDF

MODIFICARI ALE NIVELULUI SERIC DE BNP (POLIPEPTID NATRIURETIC TIP B) ASOCIATE EXACERBARILOR BRONHOPNEUMOPATIEI CRONICE OBSTRUCTIVE

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XVI, No. 3, Year 2013
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

MODIFICARI ALE NIVELULUI SERIC DE BNP (POLIPEPTID NATRIURETIC TIP B) ASOCIATE EXACERBARILOR BRONHOPNEUMOPATIEI CRONICE OBSTRUCTIVE

Simona Ştefania Bucşa, Petre Iacob Calistru and Cristina Voinea

REZUMAT

Introducere. Exacerbările bronhopneumopatiei cronice obstructive (BPOC) reprezintă principalele evenimente în evoluţia bolii care influenţează prin frecvenţa şi severitatea lor, prognosticul vital al pacientului. Impactul exacerbărilor frecvente ale bolii se manifestă prin declin rapid al funcţiei pulmonare, scăderea calităţii vieţii, creşterea inflamaţiei căilor aeriene şi mortalitate înaltă, motiv pentru care ultimele cercetări s-au concentrat asupra unor indicatori de prognostic la pacienţii cu exacerbări BPOC. BNP (Polipeptid natriuretic tip B) este secretat în principal de ventriculi, ca răspuns la supraîncărcarea de volum determinat în principal de insuficienţa cardiacă.

Scopul urmărit a fost de a preciza implicaţiile fiziopatologice şi importanţa practică a determinării şi monitorizării nivelului seric BNP corelate cu prezenţa exacerbărilor la pacienţii cu bronhopneumopatie cronică obstructivă.

Material şi metode. Cercetarea a inclus 84 pacienţi diagnosticaţi cu BPOC stabil conform criteriilor GOLD, fără semne şi simptome de hipertensiune pulmonară şi un lot martor de 70 de subiecţi sănătoşi. Studiul a fost prospectiv, s-a desfăşurat în CDT „Dr. Victor Babeş“, în perioada nov. 2011-dec. 2012. La vizita iniţială, pacienţii au fost examinaţi anamnestic şi clinic, prin spirometrie, ecocardiografie, determinarea BNP seric şi apoi au fost monitorizaţi urmărindu-se exacerbările şi relaţia cu nivelul seric al BNP. Pentru comparaţia între grupuri s-a folosit testul t-student şi test Mann Whitney U, iar diferenţele de la p < 0,05 au fost considerate semnificative.

Rezultate. Nivelul BNP plasmatic la pacienţii cu BPOC (51,0 ± 6,6 pg/ml) a fost semnificativ mai mare decât la subiecţii normali (24,2 ± 2,7 pg/ml) (p < 0,0001). Concentraţiile plasmatice de BNP la subiecţii cu BPOC stabil care au avut istoric de exacerbări cu spitalizare (67,2 ± 17,6 pg/ml) au fost semnificativ mai mari faţă de cei care nu au avut (28,3 ± 4,5 pg/ml) (p = 0,0039). Nivelul seric al BNP în timpul perioadelor de exacerbare (91,3 ± 17,3 pg/ml) a fost semnificativ mai mare decât în perioada de stabilitate a boli (52,6 ± 9,4 pg/ml) (p = 0,004) şi concentraţiile plasmatice de BNP în timpul exacerbărilor severe au fost mai mari, comparativ cu episoadele de exacerbare uşoare şi moderate (p < 0,001). Pacienţii care au necesitat spitalizare în timpul exacerbării (> 2 episoade/an) au înregistrat un nivel BNP semnificativ mai mare (102,3 ± 6,7) faţă de cei care au fost trataţi în ambulatoriu (73,6 ± 8,1) (p = 0,004).

Concluzii. Se consideră că Polipeptidul natriuretic tip B poate reprezenta un biomarker util pentru managementul pacienţilor cu exacerbare BPOC.

Cuvinte cheie: exacerbare bronhopneumopatie cronică obstructivă, BNP (Polipeptidul natriuretic tip B), biomarker

Full text | PDF

ALTERAREA PROFILULUI LIMFOCITAR TBNK IN CURSUL PNEUMONIEI BACTERIENE LA VARSTNICI

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XVI, No. 4, Year 2013
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

ALTERAREA PROFILULUI LIMFOCITAR TBNK IN CURSUL PNEUMONIEI BACTERIENE LA VARSTNICI

Iuliana Apostol de Jong, Petre Iacob Calistru, Emanoil Ceauşu, Graţiela Tardei, Maria Nica, Alma Kosa and G. Voiculescu

REZUMAT

Introducere. Pneumonia este o cauză principală de morbiditate şi mortalitate la vârstnici. Factorii care determină dezvoltarea pneumoniei sunt multipli dar unul din aceşti factorii este reprezentat de îmbătrânirea sistemului imun. Obiectivul principal al studiului a constat în identificarea modificărilor profilului populaţiilor limfocitare majore T, B şi celule NK (TBNK) din cadrul pneumoniilor bacteriene şi a profi lului TBNK asociat îmbătrânirii.

Material şi metodă. Au fost constituite trei loturi de studiu: lotul A sau lotul control, lotul B de cazuri de pneumonii bacteriene şi lotul C de subiecţi HIV+ sau modelul de îmbătrânire accelerat. Investigaţiile de laborator au inclus hemograma clasică şi imunofenotiparea TBNK. Analiza statistică s-a efectuat cu softul SPSS, versiunea 16.0. Valorile medii ale parametrilor imuni au fost comparate prin testul t student pentru variabile independente, iar valoarea p ≤0.05 a fost considerată semnificativ statistic.

Rezultate. În studiu, au fost incluşi un număr de 56 subiecţi: 26 subiecţi clinic sănătoşi, 30 subiecţi cu pneumonii şi 38 subiecţi HIV pozitivi. Prin compararea parametrilor imuni TBNK, în lotul general A versus B, am obţinut diferenţe semnificative statistic pentru T CD4 (46,9 vs. 41,6%, p=0.012). Compararea parametrilor imuni TBNK, între lotul control şi lotul HIV, a condus la diferenţe statistice pentru: T CD4+ (46,9 vs. 21,3%, p<0,001; 908 vs. 436 celule/μL, p<0,001); T CD8+ (21,9 vs. 45,9%, p<0,001; 446 vs. 919 celule/μL, p<0,001) şi CD4/CD8 (2,26 vs. 0,57, p<0,001). Lotul C a fost mai asemănător cu sublotul de vârstnici din lotul A decât cu lotul general A, ceea ce susţine ideea că lotul HIV poate fi un model de îmbătrînire accelerată, cel puţin în ceea ce priveşte imunitatea TBNK.

Concluzii. Profilul TBNK din cadrul pneumoniilor bacteriene a fost caracterizat prin scăderea T CD4+. Profi lul TBNK din infecţia HIV a fost caracterizat prin scăderea T CD4+, creşterea T CD8+ şi inversarea raportului CD4/CD8, modificări similare cu alterările descrise în statusului imun definit ca profil imun de risc (IPR+) al vârstnicilor (set de parametri imuni care Include seropozitivitatea CMV alături de modificări în compartimentul T -CD8 si CD4).

Cuvinte cheie: imunosenescenţă, imunofenotipare TBNK, HIV, îmbătrânire accelerată

Full text | PDF

THE INTRA-OBSERVER VARIABILITY OF ACOUSTIC RADIATION FORCE IMPULSE (ARFI) – IMPLICATIONS FOR THE USE OF THE METHOD IN MONITORING CHRONIC LIVER DISEASES

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XVI, No. 3, Year 2014
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

THE INTRA-OBSERVER VARIABILITY OF ACOUSTIC RADIATION FORCE IMPULSE (ARFI) – IMPLICATIONS FOR THE USE OF THE METHOD IN MONITORING CHRONIC LIVER DISEASES

George Sebastian Gherlan, Petre Iacob Calistru, Cristina Voinea and Cristian Szabo

ABSTRACT

Introduction and aims. Liver fibrosis is reversible if the cause is removed or it may progress otherwise. Noninvasive methods tend to replace liver biopsy for the assessment of liver fibrosis. There is an intra-observer variability for ARFI that has to be taken into account when this method is used for monitoring the evolution of a liver disease. We aimed to identify the level of variation between two ARFI results that reflects a real change in liver histology rather than this “normal” variability. Patients and methods. Two sets of 10 ARFI measurements were performed in 147 patients by the same observer and we computed the median and the interquartile range for each set. We assessed the variation between the two results as percentage of each result. Data regarding weight, height, age, etiology, biochemical and hematological test were collected. Results. The mean variation was of 9.84% ± 9.7%. The variability is reduced if we use IQR for validation (valid if IQR < 1/3 of the result), with a variation of 7.66% ± 7.09% in the group with both measurements valid versus 16.33% ± 13.03% in the group with at least one set invalid. ARFI was feasible in all patients ant we found an intra-observer intraclass correlation coefficient of 0.976. Conclusions. Only results with over 19.5% variation in plus or minus compared to a previous result should be considered to reflect the progression respectively regression of liver fibrosis. If IQR is used as a validation parameter, the variability is less than 15%.

Keywords: ARFI, intra-observer, hepatitis, liver fibrosis, monitoring, variability

Full text | PDF

ULTRASOUND ELASTOGRAPHY IN CHRONIC VIRAL HEPATITIS – A REVIEW

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XVI, No. 3, Year 2014
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

ULTRASOUND ELASTOGRAPHY IN CHRONIC VIRAL HEPATITIS – A REVIEW

George Sebastian Gherlan and Petre Iacob Calistru

ABSTRACT

Assessing liver fibrosis is essential for the management of chronic viral hepatitis. Over the last ten years we have been witnessing the emergence of many noninvasive methods tending to replace liver biopsy for the purpose of staging the fibrosis. There are two main classes of noninvasive methods that have demonstrated a fair ability to classify fibrosis compared to liver biopsy: the biochemical/hematological markers (also known as serologic markers) and the imaging techniques. Among the imaging techniques, ultrasound elastography has had an explosive development, with many different approaches, based on different physical principles, trying to achieve the same goal: the measurement of the stiffness of a tissue or organ. Transient elastography (TE), acoustic radiation force impulse imaging (ARFI) and shear-wave elastography (SWE) are the major players of the moment. Transient elastography is the oldest of the methods; it is validated by numerous independent studies and is already recommended by some of the main professional hepatology associations as a possible replacement for liver biopsy for the assessment of the fibrosis in chronic C hepatitis. ARFI and SWE have also been analyzed in many studies that showed their value as noninvasive liver fibrosis evaluation methods. Data abounds in the literature; the techniques are evolving so fast that even experienced ultrasonographers have trouble integrating all the information. This review is an attempt to summarize the most important data on the subject of ultrasound elastography in chronic viral hepatitis.

Keywords: liver elastography, chronic hepatitis, liver fibrosis, noninvasive, transient elastography, ARFI, shear wave elastography

Full text | PDF

UPDATES IN ANTIBIOTIC THERAPY OF BILIARY TRACT INFECTIONS

SELECT ISSUE

Romanian Journal of Infectious Diseases | Vol. XVIII, No. 1, 2015
ISSN 1454-3389  |  e-ISSN 2069-6051
ISSN-L 1454-3389
DOI: 10.37897/RJID

Indexed

DOI - Crossref
Similarity Check by iThenticate, worldwide No 1 professional plagiarism checking system
DOAJ
Scopus
NLM Catalog
Ebsco Host - Medline
Google Academic
Semantic Scholar

HIGHLIGHTS

National Awards “Science and Research”

NEW! RJID has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

UPDATES IN ANTIBIOTIC THERAPY OF BILIARY TRACT INFECTIONS

Cristian Balahura, Petre Iacob Calistru and Gabriel Constantinescu

ABSTRACT

Introduction. The management of biliary tract infections involves systemic antibiotherapy and a biliary drainage procedure. Current guidelines provide recommendations for empirical antimicrobial therapy in cholangitis but development of multi-drug resistant organisms can make many of these antibiotics ineffective. This study aimed to analyze the microbiology of bile and the susceptibility profiles of organisms identified in patients with extrahepatic cholestatis, with or without a previously placed biliary stent.

Materials and methods. We conducted a prospective study including 136 patients with biliary obstruction who were endoscopically drained between June 2014 and March 2015 in Emergency Hospital “Floreasca”, Bucharest. One hundred and four of these patients had no biliary stent in situ (group 1). Thirty-two procedures were performed in patients with at least one biliary stent in place (group 2). Microbiological examination of bile aspirates was performed and antibiotic susceptibilities were determined for the isolated bacteria.

Results. One hundred eighteen of 136 analyzed cultures were positive (81% in group 1 vs. 100% in group 2; p<0.05). In both groups, the most frequent pathogens were Escherichia coli, Klebsiella spp. and Proteus spp. The most effective antimicrobial agents against Gram-negative bacteria in group 1 and group 2 were imipenem, cefoperazone/sulbactam and piperacillin/tazobactam. Susceptibilities to ceftazidime, cefotaxime, cefepime and fluoroquinolones were significantly lower in group 2.

Conclusion. This survey shows that Gram-negative bacteria are the predominant bile pathogens found in patients with cholestatis. Cefoperazone/sulbactam, piperacillin/tazobactam or imipenem can be recommended in biliary infections. Cephalosporins and fluroquinolones should not be used as empirical therapy if a biliary stent is in place.

Keywords: biliary infection, biliary stent, antibiotics, antibiotic susceptibility

Full text | PDF



SEARCH

STANDARDE

  • Instructions for AUTHORS
  • Peer review process
  • Official Journal’s protocols
  • Pending articles

Submit article

Use this form to submit your article to the editors:

SUBMIT ARTICLE

Subscriptions

To receive the journal, please click here:

SUBSCRIBE

Partners

Conferinta Nationala de Medicina Familiei
Publicare
Abonare

plic-maileditor@rjid.com.ro

Subscribe to the Newsletter

Articles from the journal are licensed under a 
Creative Commons Attribution 4.0 International License

 Terms & Conditions

Open Access Statement

Publisher : AMALTEA Medical Publishing House

The intended audience of the site content is professionals from the medical and pharmaceutical community.
This site does not collect any personal data nor does it use cookies that might obtain such data from your browser. [ info ]
Agree
Contact

Submit ARTICLE
E-mail: editor@rjid.com.ro  |  Mobile: +4 0742.155.512, M-F 09.00-18.00 EET

SUBSCRIPTIONS
E-mail: info@amaltea.ro |  Mobile: +4 0742.155.511, M-F 09.00-18.00 EET